Cellosaurus logo
expasy logo

Cellosaurus NCI-H2373 (CVCL_A533)

[Text version]
Cell line name NCI-H2373
Synonyms H2373; H-2373; NCIH2373
Accession CVCL_A533
Resource Identification Initiative To cite this cell line use: NCI-H2373 (RRID:CVCL_A533)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136; PubMed=21642991).
  • Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=16630136).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*02:01,30:01
HLA-BB*41:01,55:01
HLA-CC*03:03,17:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.63
Native American0
East Asian, North0
East Asian, South0.91
South Asian2.63
European, North66.33
European, South29.5
Disease Pleural sarcomatoid mesothelioma (NCIt: C45663)
Pleural mesothelioma (ORDO: Orphanet_50251)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Adult
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D3S135816,18
D5S81811,13
D7S8208,11
D8S117912,15
D13S3179,12
D16S53912
D18S5117
D21S1130
FGA19,22
Penta D12
Penta E5,11
TH019.3,10
TPOX8
vWA14 (Cosmic-CLP; PubMed=25877200)
14,18 (ATCC)

Run an STR similarity search on this cell line
Publications

PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M
Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A., Mew D.J.Y., Pogrebniak H.W., Matthews W.J.
Characteristics of nine newly derived mesothelioma cell lines.
Ann. Thorac. Surg. 59:835-844(1995)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x
Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Cancer Sci. 97:387-394(2006)

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)

PubMed=21642991; DOI=10.1038/ng.855
Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-672(2011)

PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006
Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y., Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Cancer Genet. 206:191-205(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26011428; DOI=10.1111/cas.12698
Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y., Yokoi K., Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Cancer Sci. 106:990-999(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28553954; DOI=10.1038/onc.2017.147
Kato T., Sato T., Yokoi K., Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Oncogene 36:5522-5531(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31803961; DOI=10.1002/jcb.29564
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-5943 - Discontinued
Cell line databases/resources cancercelllines; CVCL_A533
Cell_Model_Passport; SIDM00103
Cosmic-CLP; 1290809
DepMap; ACH-002124
Biological sample resources BioSample; SAMN03471008
BioSample; SAMN03472607
BioSamples; SAMEA100828
Chemistry resources GDSC; 1290809
PharmacoDB; NCIH2373_1089_2019
Encyclopedic resources Wikidata; Q54907969
Experimental variables resources EFO; EFO_0006679
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
GEO; GSM726265
GEO; GSM850300
GEO; GSM1669819
Polymorphism and mutation databases Cosmic; 886391
Cosmic; 1032375
Cosmic; 1522781
Cosmic; 1541217
Cosmic; 2759213
Progenetix; CVCL_A533
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation06-Jun-2012
Last entry update05-Oct-2023
Version number35